Wegener' s granulomatosis is a distinct clinicopathologic entity characterized by granulomatous vasculitis of the upper and lower respiratory tracts together with glomerulonephritis. In addition, variable degrees of disseminated vasculitis involving both small arteries and veins may occur. A wellestablished treatment for this disease has been cyclophosphamide given orally with corticosteroids (1). However, cyclophosphamide, which is an alkylating agent similar to melphalan, chlorambucil and dihydroxybusulfan, is known to induce tumors in the classical manner associated with chemical carcinogenesis. This agent, in particular, has been related to an increased frequency of hemorrhagic cystitis (2, 3) and bladder cancer (4) (5) (6) (7) . The effect appears specific for this particular alkylating agent, which induces acute toxic effects in the bladder mucosa.
Cyclophosphamide, a widely used alkylating agent, is helpful in treating patients who have either malignant or nonneoplastic disease. After oral or intravenous administration, the drug is metabolized by hepatic microsomal enzymes to hydroxycyclophosphamide and later by target cells to phosphamide (active) and acrolein (urinary metabolite) (8) (9) (10) . The mustard component forms covalent linkages with nucleic acids of DNA(alkylation) to inhibit cell replication and produce a cytotoxic effect. Acrolein, however, is responsible for urothelial damage. Animal experiments have shown that cyclophosphamide-induced cystitis is the result of contact between toxic urine and the bladder epithelium (2, 1 1). Although the entire urinary collecting system is at risk for acrolein-mediated toxicity, the bladder is most susceptible because of its prolonged exposure to the drug. Hemorrhagic cystitis and the induction of bladder cancer are wellrecognized complications of oral cyclophosphamide therapy in patients with Wegener's granulomatosis, systemic lupus erythematosus, and rheumatoid arthritis. However, the incidence of cyclophosphamide-induced cystitis and its relation to the development of bladder cancer have not been defined (6 cyclophosphamide may exert their action in part by breaking chromosomes.This mechanismmimics an effect of ionizing radiation, which is carcinogenic to a variety of organs. Indeed, leukemia, the radiogenic tumor with the shortest latent period, has now been convincingly linked to the use of alkylating agents. In studies of ovarian cancer and myeloma
Internal Medicine Vol. 42, No. 5 (May 2003) it was estimated that the incidence of leukemia among patients surviving ten years from treatment with alkylating agents might be on the order of 12-20%. 
